Results 41 to 50 of about 267,464 (292)

Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines [PDF]

, 2011
The hemagglutinins (HAs) of human H1 and H3 influenza viruses and avian H5 influenza virus were produced as recombinant fusion proteins with the human immunoglobulin Fc domain.
Temperton, Nigel J., Ian M. Jones, Christopher R. Bailey, Eleonora Molesti, Ren, Junyuan, Jones, Ian M., Temperton, Nigel J, Silvia Loureiro, Pongsathon Phapugrangkul, Junyuan Ren, Wendy S. Barclay, Camilo A. Colaco, Molesti, Eleonora, Barclay, Wendy S., Shelton, Holly, Colaco, Camilo A, Phapugrangkul, Pongsathon, Nigel J. Temperton, Loureiro, Silvia, Barclay, Wendy S, Bailey, Christopher R, Holly Shelton, Jones, Ian, Colaco, Camilo A., Bailey, Christopher R.   +24 more
core   +1 more source

T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Frontiers in Immunology
In vitro and in silico tools help drug developers reduce unwanted immunogenicity of biologics at the design stage. These include assays that examine different immune system processes leading to anti-drug antibody (ADA) or cytotoxic cellular response ...
Sophie Tourdot, Anette Christine Karle, Marc Rosenbaum, Chloé Ackaert, Pauline Le Vu, Michael Gutknecht, Maryam Ahmadi, Annelies W. Turksma, Timothy P. Hickling   +8 more
doaj   +1 more source

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Frontiers in Immunology, 2020
Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the ...
Vibha Jawa, Frances Terry, Jochem Gokemeijer, Shibani Mitra-Kaushik, Brian J. Roberts, Sophie Tourdot, Anne S. De Groot, Anne S. De Groot   +7 more
doaj   +1 more source

Immunogenicity overview of therapeutic biologics

, 2017
<p>Hello, everyone. Welcome to watch the video named immunogenicity overview of therapeutic biologics which created by creative biolabs. In this video, we will introduce the definition of immunogenicity, background of immunogenicity and importance ...
Creative Biolabs
core   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source

Long-term humoral and cellular immune responses following Covaxin vaccination: a 2-year prospective longitudinal study

Frontiers in Immunology
BackgroundGlobally, multiple SARS-CoV-2 vaccines received emergency authorization, primarily based on adenoviral vector, mRNA, or inactivated virus platforms.
Archana Tripathy, Archana Tripathy, Sreeparna Podder, Sreeparna Podder, Swatishree Sradhanjali, Swatishree Sradhanjali, Mamuni Swain, Debdutta Bhattacharya, Debaprasad Parai, Sanghamitra Pati, Sunil K. Raghav, Sunil K. Raghav   +11 more
doaj   +1 more source

Smaller is better: nanobodies meet NMR

FEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Dendritic cell maturation assay for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Frontiers in Immunology
Early assessment and mitigation of non-clinical immunogenicity risk during early drug development is key for the development of safe and efficacious therapeutics.
Chloé Ackaert, Bruno Gonzalez-Nolasco, Marc Rosenbaum, Mercedes Perez-Olivares, Michael Gutknecht, Axel Ducret, Anette Christine Karle   +6 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange

Research and Practice in Thrombosis and Haemostasis
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel, Maria Laura Sargentini-Maier, Ana Paula Marques, Yana Vandenbossche, Gabriela Marcheva, Sriya Gunawardena, Samuel Pine   +6 more
doaj   +1 more source